SUPN Q4 2019 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$100M-13.4% YoY

Gross Profit

$96M95.9% margin

Operating Income

$41M40.6% margin

Net Income

$33M33.0% margin

EPS (Diluted)

$0.62

QoQ Revenue Growth

-1.7%

Cash Flow

Operating Cash Flow

$44M

Free Cash Flow

$42M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$565M

Stockholders' Equity

$595M

Cash & Equivalents

$181M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$100M	$116M	-13.4%
Gross Profit	$96M	$112M	-13.8%
Operating Income	$41M	$40M	+2.4%
Net Income	$33M	$26M	+27.9%

Revenue Segments

Product

$98M49%

Trokendi Xr

$75M38%

Oxtellar X R

$23M11%

Royalty

$3M1%